Chemoimmunotherapy: reengineering tumor immunity
Open accessThe DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
Abstract
Cancer chemotherapy drugs have long been considered immune suppressive. However, more recent data indicate that some cytotoxic drugs effectively treat cancer in part by facilitating an immune response to the tumor when given at the standard dose and schedule. These drugs induce a form of tumor cell death that is immunologically active, thereby inducing an adaptive immune response specific for the tumor. In addition, cancer chemotherapy drugs can promote tumor immunity through ancillary and largely unappreciated immunologic effects on both the malignant and normal host cells present within the tumor microenvironment. These more subtle immunomodulatory effects are dependent on the drug itself, its dose, and its schedule in relation to an immune-based intervention. The recent approvals of two new immune-based therapies for prostate cancer and melanoma herald a new era in cancer treatment and have led to heightened interest in immunotherapy as a valid approach to cancer treatment. A detailed understanding of the cellular and molecular basis of interactions between chemotherapy drugs and the immune system is essential for devising the optimal strategy for integrating new immune-based therapies into the standard of care for various cancers, resulting in the greatest long-term clinical benefit for cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“while reducing the levels of immunosuppressive checkpoint molecules such as PD-L1 and PD-L2, as well as VTCN1 [37].”
From The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“chemotherapy can trigger the expression of co-stimulatory molecules such as CD80 on tumor cells”
From The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors (2024) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 7×
“More recently, two clinical trials of antibodies that target the negative immune checkpoint molecule PD-1 on T cells and its ligand B7-H1/ PD-L1 on tumor cells were unexpectedly successful, with G. Chen L. A. Emens (&) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, Room 4…”
BackgroundInfluentialSafety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 7×
“More recently, two clinical trials of antibodies that target the negative immune checkpoint molecule PD-1 on T cells and its ligand B7-H1/ PD-L1 on tumor cells were unexpectedly successful, with G. Chen L. A. Emens (&) The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, Room 4…”
BackgroundInfluentialMyeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · cited 1×
“The first cancer vaccine (sipuleucel-T, Provenge) was approved for advanced prostate cancer [2], and the first immune checkpoint inhibitor targeting the negative regulatory”
BackgroundIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893 · cited 1×
“100 years as attractive strategies for cancer treatment [1].”
BackgroundApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 1×
“The clinical relevance of these immunogenic cell death pathways is suggested by the association of loss of function polymorphisms of both TLR-4 and P2RX7 with a higher risk of breast cancer relapse after adjuvant anthracyclinebased chemotherapy [11, 12].”
BackgroundCancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
Regulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature Reviews Immunology · doi:10.1038/nri1806 · Cited by 2,085
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898 · cited 1×
“The clinical relevance of these immunogenic cell death pathways is suggested by the association of loss of function polymorphisms of both TLR-4 and P2RX7 with a higher risk of breast cancer relapse after adjuvant anthracyclinebased chemotherapy [11, 12].”
BackgroundImmunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., et al. (2011) · Science · doi:10.1126/science.1208347 · Cited by 1,377
Dudley, M. E., Yang, J. C., Sherry, R., Hughes, M. S., Royal, R., Kammula, U., Robbins, P. F., Huang, J., Citrin, D. E., Leitman, S. F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5449 · Cited by 1,332
Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Martin, F., Apetoh, L., Rébé, C., & Ghiringhelli, F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3690 · Cited by 1,245
Ghiringhelli, F., Menard, C., Puig, P. E., Ladoire, S., Roux, S., Martin, F., Solary, E., Le Cesne, A., Zitvogel, L., & Chauffert, B. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0225-8 · Cited by 1,241
Diaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E., Cole, D. J., & Montero, A. J. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0523-4 · Cited by 1,215
Immunogenic and tolerogenic cell death
Green, D. R., Ferguson, T., Zitvogel, L., & Kroemer, G. (2009) · Nature Reviews Immunology · doi:10.1038/nri2545 · Cited by 1,176 · cited 1×
“A growing body of data demonstrates that some chemotherapy drugs given at their standard dose and schedule exert their antitumor effect at least in part by inducing immunogenic cell death [10].”
BackgroundImmunogenic death of colon cancer cells treated with oxaliplatin
Tesniere, A., Schlemmer, F., Boige, V, Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apetoh, L., Barault, L., et al. (2010) · Oncogene · doi:10.1038/onc.2009.356 · Cited by 1,173
Lynch, T. J., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., Sebastian, M., Neal, J., Lu, H., Cuillerot, J.-M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4032 · Cited by 1,002
Lutsiak, M. E. C., Semnani, R. T., De Pascalis, R., Kashmiri, S. V. S., Schlom, J., & Sabzevari, H. (2005) · Blood · doi:10.1182/blood-2004-06-2410 · Cited by 903
Ghiringhelli, F., Larmonier, N., Schmitt, E., Parcellier, A., Cathelin, D., Garrido, C., Chauffert, B., Solary, E., Bonnotte, B., & Martin, F. (2004) · European Journal of Immunology · doi:10.1002/eji.200324181 · Cited by 880
Walter, S., Weinschenk, T., Stenzl, A., Zdrojowy, R., Pluzanska, A., Szczylik, C., Staehler, M., Brugger, W., Dietrich, P.-Y., Mendrzyk, R., et al. (2012) · Nature Medicine · doi:10.1038/nm.2883 · Cited by 788
Naive T Cells Transiently Acquire a Memory-like Phenotype during Homeostasis-Driven Proliferation
Goldrath, A. W., Bogatzki, L. Y., & Bevan, M. J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.4.557 · Cited by 633
TH17 cells in tumour immunity and immunotherapy
Zou, W., & Restifo, N. P. (2010) · Nature Reviews Immunology · doi:10.1038/nri2742 · Cited by 624
Reck, M., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., Sebastian, M., Lu, H., Cuillerot, J.-M., & Lynch, T. J. (2013) · Annals of Oncology · doi:10.1093/annonc/mds213 · Cited by 611
Cho, B. K., Rao, V. P., Ge, Q., Eisen, H. N., & Chen, J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.4.549 · Cited by 509
Kodumudi, K. N., Woan, K., Gilvary, D. L., Sahakian, E., Wei, S., & Djeu, J. Y. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0733 · Cited by 500 · cited 1×
“Docetaxel decreases MDSC and increases CD8 T cell activity in a murine model of breast cancer [53].”
BackgroundBeyer, M., Kochanek, M., Darabi, K., Popov, A., Jensen, M., Endl, E., Knolle, P. A., Thomas, R. K., von Bergwelt-Baildon, M., Debey, S., et al. (2005) · Blood · doi:10.1182/blood-2005-02-0642 · Cited by 492
Ramakrishnan, R., Assudani, D., Nagaraj, S., Hunter, T., Cho, H.-I., Antonia, S., Altiok, S., Celis, E., & Gabrilovich, D. I. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40269 · Cited by 460
Machiels, J.-P., Reilly, R. T., Emens, L. A., Ercolini, A. M., Lei, R. Y., Weintraub, D., Okoye, F. I., & Jaffee, E. M. (2001) · PubMed · Cited by 453
Self-citationAntonia, S. J., Mirza, N., Fricke, I., Chiappori, A., Thompson, P., Williams, N., Bepler, G., Simon, G., Janssen, W., Lee, J.-H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2013 · Cited by 444 · cited 1×
“One study of DCs transduced with a p53-expressing adenoviral vector in 29 patients with extensive-stage SCLC revealed that 60 % of patients developed p53-specific immunity, but all patients except one progressed on study [100].”
BackgroundEric, L., Yeo, C. J., Lillemoe, K. D., Biedrzycki, B., Kobrin, B., Herman, J., Sugar, E., Piantadosi, S., Cameron, J. L., Solt, S., et al. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e3181fd271c · Cited by 403
Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response
Ercolini, A. M., Ladle, B. H., Manning, E. A., Pfannenstiel, L. W., Armstrong, T. D., Machiels, J.-P. H., Bieler, J. G., Emens, L. A., Reilly, R. T., & Jaffee, E. M. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042167 · Cited by 399
Self-citationMackall, C. L., Bare, C. V., Granger, L. A., Sharrow, S. O., Titus, J. A., & Gress, R. E. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.12.4609 · Cited by 397
Immunogenic Tumor Cell Death for Optimal Anticancer Therapy: The Calreticulin Exposure Pathway
Zitvogel, L., Kepp, O., Senovilla, L., Menger, L., Chaput, N., & Kroemer, G. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2891 · Cited by 387
Le, H. K., Graham, L., Cha, E., Morales, J. K., Manjili, M. H., & Bear, H. D. (2009) · International Immunopharmacology · doi:10.1016/j.intimp.2009.03.015 · Cited by 368
Kawasaki, K., Akashi, S., Shimazu, R., Yoshida, T., Miyake, K., & Nishijima, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.4.2251 · Cited by 355
Laheru, D., Lutz, E., Burke, J., Biedrzycki, B., Solt, S., Onners, B., Tartakovsky, I., Nemunaitis, J., Le, D., Sugar, E., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0371 · Cited by 346
Demaria, S., Volm, M., Shapiro, R. L., Yee, H. T., Oratz, R., Formenti, S. C., Muggia, F. M., & Symmans, W. F. (2001) · PubMed · Cited by 303
Vaccination Elicits Correlated Immune and Clinical Responses in Glioblastoma Multiforme Patients
Wheeler, C. J., Black, K. L., Liu, G., Mazer, M., Zhang, X.-X., Pepkowitz, S., Goldfinger, D., Ng, H., Irvin, D., & Yu, J. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5973 · Cited by 296
Rapoport, A. P., Stadtmauer, E. A., Aqui, N., Badros, A., Cotte, J., Chrisley, L., Veloso, E., Zheng, Z., Westphal, S., Mair, R., et al. (2005) · Nature Medicine · doi:10.1038/nm1310 · Cited by 290
Arlen, P. M., Gulley, J. L., Parker, C., Skarupa, L., Pazdur, M., Panicali, D., Beetham, P., Tsang, K. Y., Grosenbach, D. W., Feldman, J., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2059 · Cited by 287
The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol
Byrd-Leifer, C. A., Block, E. F., Takeda, K., Akira, S., & Ding, A. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200108)31:8<2448::aid-immu2448>3.0.co;2-n · Cited by 287
Miles, D., Roché, H., Martin, M., Perren, T. J., Cameron, D. A., Glaspy, J., Dodwell, D., Parker, J., Mayordomo, J., Tres, A., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0307 · Cited by 262
Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model
Banissi, C., Ghiringhelli, F., Chen, L., & Carpentier, A. F. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-009-0671-1 · Cited by 255
Brignone, C., Gutierrez, M., Mefti, F., Brain, E., Jarcau, R., Cvitkovic, F., Bousetta, N., Medioni, J., Gligorov, J., Grygar, C., et al. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-71 · Cited by 255
Shurin, G. V., Tourkova, I. L., Kaneno, R., & Shurin, M. R. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900734 · Cited by 242
Emens, L. A., Asquith, J. M., Leatherman, J. M., Kobrin, B. J., Petrik, S., Laiko, M., Levi, J., Daphtary, M. M., Biedrzycki, B., Wolff, A. C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3494 · Cited by 236
Self-citationGhebeh, H., Lehe, C., Barhoush, E., Al-Romaih, K., Tulbah, A., Al-Alwan, M., Hendrayani, S.-F., Manogaran, P., Alaiya, A., Al-Tweigeri, T., et al. (2010) · Breast Cancer Research · doi:10.1186/bcr2605 · Cited by 234
Warren, E. H., Fujii, N., Akatsuka, Y., Chaney, C. N., Mito, J. K., Loeb, K. R., Gooley, T. A., Brown, M. L., Koo, K. K. W., Rosinski, K. V., et al. (2010) · Blood · doi:10.1182/blood-2009-10-248997 · Cited by 231
Zhang, L., Dermawan, K., Jin, M., Liu, R., Zheng, H., Xu, L., Zhang, Y., Cai, Y., Chu, Y., & Xiong, S. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.07.013 · Cited by 209
Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines
Taieb, J., Chaput, N., Schartz, N., Roux, S., Novault, S., Ménard, C., Ghiringhelli, F., Terme, M., Carpentier, A. F., Darrasse-Jèse, G., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.5.2722 · Cited by 200
Schiavoni, G., Mattei, F., Di Pucchio, T., Santini, S. M., Bracci, L., Belardelli, F., & Proietti, E. (2000) · Blood · doi:10.1182/blood.v95.6.2024 · Cited by 196
Correale, P., Cusi, M. G., Tsang, K. Y., Del Vecchio, M. T., Marsili, S., Placa, M. L., Intrivici, C., Aquino, A., Micheli, L., Nencini, C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.147 · Cited by 171
Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients
Viaud, S., Flament, C., Zoubir, M., Pautier, P., LeCesne, A., Ribrag, V., Soria, J.-C., Marty, V., Vielh, P., Robert, C., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1259 · Cited by 170
von Mehren, M., Arlen, P. M., Gulley, J. L., Rogatko, A., Cooper, H. S., Meropol, N. J., Alpaugh, R. K., Davey, M., McLaughlin, S. B., Beard, M., et al. (2001) · PubMed · Cited by 170
Borrello, I., Sotomayor, E. M., Rattis, F.-M., Cooke, S. K., Gu, L., & Levitsky, H. I. (2000) · Blood · doi:10.1182/blood.v95.10.3011 · Cited by 167
Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice
Pfannenstiel, L. W., Lam, S. S. K., Emens, L. A., Jaffee, E. M., & Armstrong, T. D. (2010) · Cellular Immunology · doi:10.1016/j.cellimm.2010.03.001 · Cited by 159
Self-citationBrunsvig, P. F., Kyte, J. A., Kersten, C., Sundstrøm, S., Møller, M., Nyakas, M., Hansen, G. L., Gaudernack, G., & Aamdal, S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1385 · Cited by 159
Tseng, C.-W., Hung, C.-F., Alvarez, R. D., Trimble, C., Huh, W. K., Kim, D., Chuang, C.-M., Lin, C.-T., Tsai, Y.-C., He, L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0037 · Cited by 158
Kaneno, R., Shurin, G. V., Tourkova, I. L., & Shurin, M. R. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-58 · Cited by 155
Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model
Wada, S., Yoshimura, K., Hipkiss, E. L., Harris, T. J., Yen, H.-R., Goldberg, M. V., Grosso, J. F., Getnet, D., Demarzo, A. M., Netto, G. J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4102 · Cited by 152
Nakahara, T., Uchi, H., Lesokhin, A. M., Avogadri, F., Rizzuto, G. A., Hirschhorn-Cymerman, D., Panageas, K. S., Merghoub, T., Wolchok, J. D., & Houghton, A. N. (2010) · Blood · doi:10.1182/blood-2009-11-251231 · Cited by 134
Fonsatti, E., Nicolay, H. J. M., Sigalotti, L., Calabrò, L., Pezzani, L., Colizzi, F., Altomonte, M., Guidoboni, M., Marincola, F. M., & Maio, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3091 · Cited by 131
Hermans, I. F., Chong, T. W., Palmowski, M. J., Harris, A. L., & Cerundolo, V. (2003) · PubMed · Cited by 128
Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer
Kaufman, H. L., Lenz, H., Marshall, J. L., Singh, D., Garrett, C. R., Cripps, C., Moore, M. J., von Mehren, M., Dalfen, R., Heim, W. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0276 · Cited by 127
Chu, C., Boyer, J., Schullery, D. S., Gimotty, P. A., Gamerman, V., BENDER, J. G., Levine, B. L., Coukos, G., Rubin, S. C., Morgan, M. A., et al. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1081-8 · Cited by 118
Salem, M. L., Díaz-Montero, C. M., Al-Khami, A. A., El-Naggar, S. A., Naga, O., Montero, A. J., Khafagy, A., & Cole, D. J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801829 · Cited by 115
Kyte, J. A., Gaudernack, G., Dueland, S., Trachsel, S., Julsrud, L., & Aamdal, S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0184 · Cited by 113
Ho, V. T., Vanneman, M., Kim, H., Sasada, T., Kang, Y. J., Pasek, M., Cutler, C., Koreth, J., Alyea, E., Sarantopoulos, S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908358106 · Cited by 109
Adair, S. J., & Hogan, K. T. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0582-6 · Cited by 108
T-regulatory cell modulation: the future of cancer immunotherapy?
Nizar, S. A., Copier, J. P., Meyer, B., Bodman‐Smith, M. D., Galustian, C., Kumar, D., & Dalgleish, A. G. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605040 · Cited by 107
Radojcic, V., Bezak, K. B., Skarica, M., Pletneva, M. A., Yoshimura, K., Schulick, R. D., & Luznik, L. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-009-0734-3 · Cited by 106
Chemotherapy enhances vaccine‐induced antitumor immunity in melanoma patients
Nisticò, P., Capone, I., Palermo, B., Del Bello, D., Ferraresi, V., Moschella, F., Aricò, E., Valentini, M., Bracci, L., Cognetti, F., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.23886 · Cited by 106
Borrello, I., Levitsky, H. I., Stock, W., Sher, D., Lu, Q., DeAngelo, D. J., Alyea, E. P., Stone, R. M., Damon, L. E., LINKER, C. A., et al. (2009) · Blood · doi:10.1182/blood-2009-02-205278 · Cited by 104
Kaneno, R., Shurin, G. V., Kaneno, F. M., Naiditch, H., Luo, J., & Shurin, M. R. (2011) · Cellular Oncology · doi:10.1007/s13402-010-0005-5 · Cited by 99
Eralp, Y., Wang, X., Wang, J., Maughan, M. F., Polo, J. M., & Lachman, L. B. (2004) · Breast Cancer Research · doi:10.1186/bcr787 · Cited by 99
van der Most, R. G., Currie, A. J., Cleaver, A. L., Salmons, J., Nowak, A. K., Mahendran, S., Larma, I., Prosser, A., Robinson, B. W. S., Smyth, M. J., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006982 · Cited by 97
Chen, C., Ho, C., Chang, M., Sun, W.-Z., Chen, Y., Chiang, Y., Syu, M.-H., Hsieh, C., & Cheng, W. (2010) · Molecular Therapy · doi:10.1038/mt.2010.34 · Cited by 96
Teshima, T., Mach, N., Hill, G. R., Pan, L.-L., Gillessen, S., Dranoff, G., & Ferrara, J. L. M. (2001) · PubMed · Cited by 94
Correale, P., Aquino, A., Giuliani, A., Pellegrini, M., Micheli, L., Cusi, M. G., Nencini, C., Petrioli, R., Prete, S. P., Vecchis, L. D., et al. (2003) · International Journal of Cancer · doi:10.1002/ijc.10969 · Cited by 90
Yang, S., & Haluska, F. G. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.7.4599 · Cited by 81
Moschella, F., Valentini, M., Aricò, E., Macchia, I., Sestili, P., D'Urso, M. T., Alessandri, C., Belardelli, F., & Proietti, E. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4523 · Cited by 79
Ding, Z., Blazar, B. R., Mellor, A. L., Munn, D. H., & Zhou, G. (2010) · Blood · doi:10.1182/blood-2009-11-253336 · Cited by 78
Gameiro, S. R., Caballero, J. A., Higgins, J. P., Apelian, D., & Hodge, J. W. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1020-8 · Cited by 78
Correale, P., Tagliaferri, P., Fioravanti, A., Del Vecchio, M. T., Remondo, C., Montagnani, F., Rotundo, M. S., Ginanneschi, C., Martellucci, I., Francini, E., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5278 · Cited by 78
Chemotherapy: friend or foe to cancer vaccines?
Emens, L. A., Machiels, J., Reilly, R. T., & Jaffee, E. M. (2001) · PubMed · Cited by 76
Self-citationDifferential effects of Paclitaxel on dendritic cell function
John, J., Ismail, M., Riley, C., Askham, J., Morgan, R., Melcher, A., & Pandha, H. (2010) · BMC Immunology · doi:10.1186/1471-2172-11-14 · Cited by 75
Kanakry, C. G., Hess, A. D., Gocke, C. D., Thoburn, C. J., Kos, F. J., Meyer, C. F., Briel, J., Luznik, L., Smith, B. D., Levitsky, H. I., et al. (2010) · Blood · doi:10.1182/blood-2010-04-277939 · Cited by 74
Palermo, B., Bello, D. D., Sottini, A., Serana, F., Ghidini, C., Gualtieri, N., Ferraresi, V., Catricalà, C., Belardelli, F., Proietti, E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1326 · Cited by 70
Salem, M. L., Al-Khami, A. A., El-Naggar, S. A., Diaz-Montero, C. M., Chen, Y., & Cole, D. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902309 · Cited by 70
Chu, Y., Wang, L.-X., Yang, G., Ross, H. J., Urba, W. J., Prell, R., Jooss, K., Xiong, S., & Hu, H.-M. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000199198.43587.ba · Cited by 69
Luznik, L., Slansky, J. E., Jalla, S., Borrello, I., Levitsky, H. I., Pardoll, D. M., & Fuchs, E. J. (2003) · Blood · doi:10.1182/blood-2002-07-2233 · Cited by 67
Wang, J., Kobayashi, M., Han, M., Choi, S., Takano, M., Hashino, S., Tanaka, J., Kondoh, T., Kawamura, K., & Hosokawa, M. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03645.x · Cited by 65
Weihrauch, M. R., Ansén, S., Jurkiewicz, E., Geisen, C., Xia, Z., Anderson, K. S., Gracien, E., Schmidt, M., Wittig, B., Diehl, V., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0018 · Cited by 65
Alfaro, C., Perez-Gracia, J. L., Suarez, N., Rodriguez, J., Fernandez de Sanmamed, M., Sangro, B., Martin-Algarra, S., Calvo, A., Redrado, M., Agliano, A., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1102209 · Cited by 60
Cytosine arabinoside induces costimulatory molecule expression in acute myeloid leukemia cells
Vereecque, R., Saudemont, A., & Quesnel, B. (2004) · Leukemia · doi:10.1038/sj.leu.2403391 · Cited by 55
Melphalan and Other Anticancer Modalities Up-Regulate B7-1 Gene Expression in Tumor Cells
Sojka, D. K., Donepudi, M., Bluestone, J. A., & MOKYR, M. B. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6230 · Cited by 54
Morre, M., & Beq, S. (2012) · Targeted Oncology · doi:10.1007/s11523-012-0210-4 · Cited by 51
Salem, M. L., El-Naggar, S. A., & Cole, D. J. (2009) · Cellular Immunology · doi:10.1016/j.cellimm.2009.11.011 · Cited by 48
Vacchelli, E., Galluzzi, L., Rousseau, V., Rigoni, A., Tesniere, A., Delahaye, N., Schlemmer, F., Menger, L., Sukkurwala, A. Q., Adjemian, S., et al. (2012) · OncoImmunology · doi:10.4161/onci.18684 · Cited by 45
Teshima, T., Liu, C., Lowler, K. P., Dranoff, G., & Ferrara, J. L. M. (2002) · PubMed · Cited by 36
Mechanism of Melphalan-Induced B7-1 Gene Expression in P815 Tumor Cells
Donepudi, M., Raychaudhuri, P., Bluestone, J. A., & MOKYR, M. B. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6491 · Cited by 33
Prell, R. A., Gearin, L., Simmons, A. D., VanRoey, M. J., & Jooss, K. U. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0116-4 · Cited by 32
Specific immunotherapy with vaccinia oncolysates
Wallack, M. K. (1981) · Cancer Immunology Immunotherapy · doi:10.1007/bf00200305 · Cited by 27
Toward a breast cancer vaccine: work in progress.
Emens, L. A., & Jaffee, E. M. (2003) · PubMed · Cited by 23
Self-citationChopra, A., Kim, T. S., O‐Sullivan, I., Martinez, D., & Cohen, E. P. (2006) · International Journal of Cancer · doi:10.1002/ijc.21724 · Cited by 19
GM-CSF-secreting vaccines for solid tumors.
Emens, L. A. (2009) · PubMed · Cited by 17
Self-citationSchiller, J. H., Nemunaitis, J. J., Ross, H. J., Jablons, D. M., Harper, H., Sterman, D., Kelly, K. M., Carbone, D. P., Lin, A., & Hege, K. M. (2005) · Lung Cancer · doi:10.1016/s0169-5002(05)80414-3 · Cited by 11
Immunotherapy and Cancer Therapeutics: Why Partner?
Emens, L. A., & Jaffee, E. M. (2007) · Elsevier eBooks · doi:10.1016/b978-012372551-6/50076-6 · Cited by 9
Self-citationNemunaitis, J. J., Schiller, J. H., Ross, H. J., Jablons, D. M., Harper, H., Sterman, D., Kelly, K. L., Carbone, D. P., Lin, A., Maslyar, D. J., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.08.705 · Cited by 5
Cited by
Nanotechnology for Multimodal Synergistic Cancer Therapy
Fan, W., Yung, B., Huang, P., & Chen, X. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00258 · Cited by 1,791
Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 870
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
Emens, L. A., & Middleton, G. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0064 · Cited by 831
Self-citationClinical use of dendritic cells for cancer therapy
Anguille, S., Smits, E. L., Lion, E., van Tendeloo, V. F., & Berneman, Z. N. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70585-0 · Cited by 700
Peng, J., Hamanishi, J., Matsumura, N., Abiko, K., Murat, K., Baba, T., Yamaguchi, K., Horikawa, N., Hosoe, Y., Murphy, S. K., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3098 · Cited by 525
Metadata
- Authors
- Chen, G., & Emens, L. A.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Emens, Leisha A.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2013-02
- Volume
- 62
- Issue
- 2
- Pages
- 203-216
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC3608094
- OpenAlex
- W2089905323
- Cited by
- 242
- References
- 114
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 16 · 2023: 24 · 2022: 21 · 2021: 24 · 2020: 29 · 2019: 21 · 2018: 21 · 2017: 15 · 2016: 13 · 2015: 16 · 2014: 19 · 2013: 6
- FWCI
- 1.85
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Cancer Immunology Immunotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Johns Hopkins University
- Genentech
- National Cancer Institute (P50CA088843)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- chemoimmunotherapy, antitumor immunity, tumor microenvironment, immunomodulation, immune checkpoint inhibitors, prostate cancer, melanoma, combination therapy, dose and schedule
- MeSH terms
- Animals, Antineoplastic Agents, Clinical Trials as Topic, Dendritic Cells, Humans, Immunotherapy, Neoplasms, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.